Traditional Chinese medicine for preventing and treating ischemic cardiovascular and cerebrovascular diseases
A cardiovascular and cerebrovascular disease, ischemic technology, applied in the direction of cardiovascular system diseases, blood diseases, metabolic diseases, etc., can solve the disease remission rate, virus clearance rate, effective prevention and treatment, unsatisfactory clinical cure rate, adverse reactions To achieve strong prevention and treatment effects, no toxic side effects, and lower blood lipids
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Example Embodiment
[0018] Example 1: The present invention will be further described in detail below in conjunction with examples: a traditional Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular diseases, which is made from the following raw materials in parts by weight:
[0019] The formula of the present invention according to weight unit parts is: 3.0 parts of ginseng, 3.0 parts of panax notoginseng, 2.0 parts of leech, 3.0 parts of kudzu root, and 1.0 part of amber. The above-mentioned pharmaceutical raw materials are mixed, crushed, passed through a 100-mesh sieve, and then filled into capsules. Each capsule contains 0.45 grams of Chinese medicine powder.
[0020] Treatment of 567 patients with coronary heart disease, the drug of this example, also used the above diagnosis basis, efficacy criteria and treatment methods to conduct clinical trials. After a course of treatment, the treatment result: basically cured (clinical symptoms were basically eliminated) 296 ...
Example Embodiment
[0021] Example 2: The present invention will be further described in detail below in conjunction with examples: a traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases, which is made from the following raw materials in parts by weight:
[0022] The formula of the present invention according to weight unit parts is: 3.0 parts of ginseng, 3.0 parts of panax notoginseng, 2.0 parts of leech, 1.0 part of kudzu root, and 2.0 parts of amber. The above-mentioned pharmaceutical raw materials are mixed, crushed, passed through a 100-mesh sieve, and then filled into capsules. Each capsule contains 0.45 grams of Chinese medicine powder.
[0023] Treatment of 107 patients with coronary heart disease, the drug of this example, also used the above diagnosis basis, efficacy criteria and treatment methods to conduct clinical trials. After a course of treatment, the treatment results: 25 people were basically cured, 79 people were significantly relieved, an...
Example Embodiment
[0024] Example 3: The following examples will further describe the present invention in detail: a traditional Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular diseases, which is made from the following raw materials in parts by weight: The formula of the present invention in units of weight is: Ginseng 3.0 Parts, 3.0 parts of Panax notoginseng, 2.0 parts of leech, 5.0 parts of Pueraria lobata, 3.0 parts of amber. The above-mentioned pharmaceutical raw materials are mixed, crushed, passed through a 100-mesh sieve, and then filled into capsules. Each capsule contains 0.45 grams of Chinese medicine powder.
[0025] Treating 38 patients with coronary heart disease, the drugs of this example also used the above diagnostic basis, efficacy criteria and treatment methods to conduct clinical trials. After a course of treatment, the treatment results: basically cured 6 patients, significantly relieved 29 patients, and the effective remission rate was 92.1...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap